DNA damage and faulty repair jointly cause mutations

May 01, 2020

Researchers at EMBL's European Bioinformatics Institute (EMBL-EBI), the University of Dundee and the Wellcome Sanger Institute analysed over 2700 genomes from C. elegans worms in order to better understand the causes of mutations. Their findings, published today in Nature Communications, characterise how DNA mutations result from the combined action of DNA damage and inaccurate DNA repair mechanisms.

A cell's DNA is constantly exposed to physical and chemical stresses - or genotoxins - that can damage it and cause mutations. However, cells have a myriad of repair mechanisms to fix DNA lesions soon after they arise. Occasionally, the restorative repair process fails, either by making extra errors, or by failing to detect the DNA lesions altogether. This leads to mutations, which are the root cause of cancer.

Many genotoxins, like those found in tobacco smoke, were thought to cause a unique suite of mutations in the genome, recognisable as a mutational signature. "Detecting such signatures in cancer allows scientists to trace what caused the damage in the first place, and aid prognosis and treatment by pointing to certain vulnerabilities," explains Nadezda Volkova, recent PhD graduate at EMBL-EBI.

However, many mutational signatures observed in cancer genomes do not seem to relate to any single genotoxin and others appear to result from a combination of factors. To understand the origin of these signatures, Volkova and colleagues tested the effects of more than 150 combinations of twelve genotoxins on C. elegans worms whose DNA repair mechanisms were either unaltered or faulty. The scientists experimentally demonstrated that mutational signatures result from a combined action of DNA damage and specific repair mechanisms.

DNA repair and mutational signatures

"A lot of DNA alterations that we observed in our study occur in human cancer as well, but we found that mutational signatures are more variable than we previously thought," says Volkova.

The scientists found that different types of DNA alterations induced by the same genotoxin are often fixed by different DNA repair pathways, some error-free, others error-prone. As a result, a single genotoxin may leave a variety of mutational signatures at various rates, depending on the repair process.

While most DNA repair prevents mutations, it can also cause them. For example, Volkova and colleagues demonstrated that one particular mechanism, called translesion synthesis, is responsible for the majority of base mutations caused by genotoxin exposure as a trade-off for more severe and potentially more deleterious mutations. While many of these minor mutations may be harmless, in humans they can increase the probability of developing a tumour.

"In cancer genomics, there is an implicit expectation that for every signature, one could find a single cause: our analysis challenges that expectation. Behind each pattern, there are at least two unknowns: the damage that occurs and the repair capacity of the cell," says Moritz Gerstung, Group Leader at EMBL-EBI.

Bringing together cancer genomics and DNA repair

While the molecular mechanisms of DNA repair are very well-established, the exact types and frequency of mutations they can generate remained unclear until high-throughput sequencing entered the scene.

This study combines whole genome sequencing with an experimental screen to better understand the causes of mutational signatures. The results have potential implications for cancer research, diagnosis and treatment.

"Understanding the interplay between DNA damage and repair helps to better gauge the risk of cancer predisposition, and to understand the response to cancer treatment," says Bettina Meier, Senior Research Associate at the University of Dundee.

Mutational signatures have become a pillar of cancer genome analysis because they may shed light on the carcinogens cancer cells have been exposed to, and the repair mechanisms that were perturbed.

However, not all observed mutational signatures and their individual facets are fully understood. An experimental approach ensures that the observed patterns are the direct consequences of the conditions set by the scientists. It also helps understand how multiple DNA repair processes jointly shape mutational signatures.

"It took years to generate all these repair defective C. elegans, to systematically expose them to a panel of genotoxins, and to prepare, sequence and analyse their DNA. It is great to see that experimental work on C. elegans is directly relevant for interpreting cancer genomes," says Anton Gartner, Group Leader at the University of Dundee, recently appointed Associate Director of the IBS Center for Genomic Integrity at UNIST Ulsan, South Korea.
European Bioinformatics Institute (EMBL-EBI)

The European Bioinformatics Institute (EMBL-EBI) is a global leader in the storage, analysis and dissemination of large biological datasets. We help scientists realise the potential of 'big data' by enhancing their ability to exploit complex information to make discoveries that benefit humankind.

We are at the forefront of computational biology research, with work spanning sequence analysis methods, multi-dimensional statistical analysis and data-driven biological discovery, from plant biology to mammalian development and disease.

We are part of EMBL and are located on the Wellcome Genome Campus, one of the world's largest concentrations of scientific and technical expertise in genomics.

Website: http://www.ebi.ac.uk

European Molecular Biology Laboratory - European Bioinformatics Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.